Gut Microbiota is Not Modified by Randomized, Double-Blind, Placebo-Controlled Trial of VSL#3 in Diarrhea-Predominant Irritable Bowel Syndrome

Probiotics and Antimicrobial Proteins

Volumn 3, Issue 1, 2011, Pages 1-7

  Michail, Sonia ^a   Kenche, Harshavardhan ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

Author keywords

Diarrhea; Irritable bowel syndrome; Microbiota; Probiotics

Indexed keywords

PLACEBO; PROBIOTIC AGENT; VSL3;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DNA FRAGMENTATION; DNA ISOLATION; DOUBLE BLIND PROCEDURE; FECES MICROFLORA; HIGH THROUGHPUT SCREENING; HUMAN; INTESTINE FLORA; IRRITABLE COLON; MICROARRAY ANALYSIS; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS);

EID: 79952490208     PISSN: 18671306     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12602-010-9059-y     Document Type: Article

References (44)

1. Suau S (2003) Molecular tools to investigate intestinal bacterial communities. J Pediatr Gastroenterol Nutr 37(3): 222-224.
2. Treem WR, Ahsan N, Kastoff G, Hyams JS (1996) Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation. J Pediatr Gastroenterol Nutr 23(3): 280-286.
3. King TS, Elia M, Hunter JO (1998) Abnormal colonic fermentation in irritable bowel syndrome. Lancet 352(9135): 1187-1189.
4. Pimentel M, Mayer AG, Park S, Chow EJ, Hasan A, Kong Y (2003) Methane production during lactulose breath test is associated with gastrointestinal disease presentation. Dig Dis Sci 48(1): 86-92.
5. Pimentel M, Kong Y, Park S (2004) IBS subjects with methane on lactulose breath test have lower postprandial serotonin levels than subjects with hydrogen. Dig Dis Sci 49(1): 84-87.
6. Codling C, O'Mahony L, Shanahan F, Quigley EM, Marchesi JR (2009) A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci 55(2): 392-397.
7. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S (2009) Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 22(5): 512-519, 114-515.
8. Parkes GC, Brostoff J, Whelan K, Sanderson JD (2008) Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol 103(6): 1557-1567.
9. Kassinen A, Krogius-Kurikka L, Makivuokko H, Rinttila T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A (2007) The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133(1): 24-33.
10. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P (2009) A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 9: 15.
11. Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M (2008) Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum 51(12): 1775-1780.
12. McFarland LV, Dublin S (2008) Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 14(17): 2650-2661.
13. Brigidi P, Vitali B, Swennen E, Bazzocchi G, Matteuzzi D (2001) Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol 152(8): 735-741.
14. Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, Zinsmeister AR (2003) A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 17(7): 895-904.
15. Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, Thomforde G, Zinsmeister AR (2005) A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 17(5): 687-696.
16. Paliy O, Kenche H, Abernathy F, Michail S (2009) High-throughput quantitative analysis of the human intestinal microbiota with a phylogenetic microarray. Appl Environ Microbiol 75(11): 3572-3579.
17. Collins SM (1996) The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology 111(6): 1683-1699.
18. Drossman DA, Camilleri M, Mayer EA, Whitehead WE (2002) AGA technical review on irritable bowel syndrome. Gastroenterology 123(6): 2108-2131.
19. Quigley EM (2003) Current concepts of the irritable bowel syndrome. Scand J Gastroenterol 38(Suppl 237): 1-8.
20. Bradley HK, Wyatt GM, Bayliss CE, Hunter JO (1987) Instability in the faecal flora of a patient suffering from food-related irritable bowel syndrome. J Med Microbiol 23(1): 29-32.
21. Gorbach SL (2002) Probiotics in the third millennium. Dig Liver Dis 34(Suppl 2): S2-S7.
22. von Wright A, Salminen S (1999) Probiotics: established effects and open questions. Eur J Gastroenterol Hepatol 11(11): 1195-1198.
23. Isolauri E, Kirjavainen PV, Salminen S (2002) Probiotics: a role in the treatment of intestinal infection and inflammation? Gut 50(Suppl 3): III54-III59.
24. McCarthy J, O'Mahony L, O'Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, Fitzgibbon J, O'Sullivan GC, Kiely B, Collins JK et al (2003) Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 52(7): 975-980.
25. O'Mahony L, Feeney M, O'Halloran S, Murphy L, Kiely B, Fitzgibbon J, Lee G, O'Sullivan G, Shanahan F, Collins JK (2001) Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther 15(8): 1219-1225.
26. Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA (1999) Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 276(4 Pt 1): G941-G950.
27. Michail S, Abernathy F (2003) Lactobacillus plantarum inhibits the intestinal epithelial migration of neutrophils induced by enteropathogenic Escherichia coli. J Pediatr Gastroenterol Nutr 36(3): 385-391.
28. Jiang T, Savaiano DA (1997) In vitro lactose fermentation by human colonic bacteria is modified by Lactobacillus acidophilus supplementation. J Nutr 127(8): 1489-1495.
29. Jiang T, Mustapha A, Savaiano DA (1996) Improvement of lactose digestion in humans by ingestion of unfermented milk containing Bifidobacterium longum. J Dairy Sci 79(5): 750-757.
30. Jiang T, Savaiano DA (1997) Modification of colonic fermentation by Bifidobacteria and pH in vitro. Impact on lactose metabolism, short-chain fatty acid, and lactate production. Dig Dis Sci 42(11): 2370-2377.
31. Ouwehand AC, Isolauri E, Kirjavainen PV, Tolkko S, Salminen SJ (2000) The mucus binding of Bifidobacterium lactis Bb12 is enhanced in the presence of Lactobacillus GG and Lact. delbrueckii subsp. bulgaricus. Lett Appl Microbiol 30(1): 10-13.
32. Ouwehand AC, Lagstrom H, Suomalainen T, Salminen S (2002) Effect of probiotics on constipation, fecal azoreductase activity and fecal mucin content in the elderly. Ann Nutr Metab 46(3-4): 159-162.
33. Ford AC, Talley NJ, Quigley EM, Moayyedi P (2009) Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum 52(10): 1805 (author reply 1806).
34. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS (2009) The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 104(4): 1033-1049 (quiz 1050).
35. Bausserman M, Michail S (2005) The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr 147(2): 197-201.
36. Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B (2000) Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 95(5): 1231-1238.
37. Tsuchiya J, Barreto R, Okura R, Kawakita S, Fesce E, Marotta F (2004) Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis 5(4): 169-174.
38. Halpern GM, Prindiville T, Blankenburg M, Hsia T, Gershwin ME (1996) Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. Am J Gastroenterol 91(8): 1579-1585.
39. Hamilton-Miller J (2001) Probiotics in the management of irritable bowel syndrome: a review of clinical trials. Microb Ecol Health Dis 13: 212-216.
40. Gaudier E, Michel C, Segain JP, Cherbut C, Hoebler C (2005) The VSL# 3 Probiotic Mixture Modifies Microflora but Does Not Heal Chronic Dextran-Sodium Sulfate-Induced Colitis or Reinforce the Mucus Barrier in Mice. J Nutr 135(12): 2753-2761.
41. Langendijk PS, Schut F, Jansen GJ, Raangs GC, Kamphuis GR, Wilkinson MH, Welling GW (1995) Quantitative fluorescence in situ hybridization of Bifidobacterium spp. with genus-specific 16S rRNA-targeted probes and its application in fecal samples. Appl Environ Microbiol 61(8): 3069-3075.
42. Wilson KH, Blitchington RB (1996) Human colonic biota studied by ribosomal DNA sequence analysis. Appl Environ Microbiol 62(7): 2273-2278.
43. Suau A, Bonnet R, Sutren M, Godon JJ, Gibson GR, Collins MD, Dore J (1999) Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl Environ Microbiol 65(11): 4799-4807.
44. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444(7122): 1027-1031.